The aim of this study has been to investigate the plasma endothelin-1
(ET-1) levels in adult patients with proven Addison's disease (AD). Pl
asma ET-1 levels were measured in 29 subjects (17 males and 12 females
, aged between 20 and 54 years): 15 of them were patients with AD and
14 were sex- and age-matched normal subjects, used as a control group.
All patients with AD have been studied under basal conditions and nin
e of them also after 2 weeks on oral corticosteroid therapy (individua
l cortisol dosage ranging from 25 to 37.5 mg/day and 0.1 mg/day 9 alph
a-fluorohydrocortisone). Extracted plasma ET-1 was determined by a spe
cific radioimmunoassay using rabbit endothelin antisera. Mean ET-1 val
ues in the patients with AD were three times higher than in normal sub
jects (21.09 +/- 4.38 pg/ml vs 6.72 +/- 1.74 pg/ml; p < 0.0001). Plasm
a ET-1 levels assayed in the patients with AD after 2 weeks of cortico
steroid therapy were significantly decreased (14.47 +/- 3.7 pg/ml vs 2
2.8 +/- 5.2 pg/ml; -37%; p < 0.001) compared to values in untreated pa
tients. However, the plasma ET-1 values obtained following corticoster
oid therapy were still significantly higher (p < 0.001) than those det
ected in the control subjects. These results clearly indicate that pat
ients with untreated AD have increased circulating ET-1 levels that ma
y be reduced by short-term corticosteroid therapy.